IDRA - イデラ・ファ―マシュ―ティカルズ （Idera Pharmaceuticals Inc.）

Idera Pharma Earnings, Revenue Beat in Q3

Idera Pharmaceuticals press release (IDRA): Q3 GAAP EPS of -$0.06.Revenue of $0.05M.The Company’s pro forma cash position as of September 30, 2022 was $26.8 million.

EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better

Idera Pharmaceuticals Inc (NASDAQ: IDRA ) acquired Aceragen Inc , a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023 , funding the advancement of Aceragen''s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from … Full story available on Benzinga.com

Idera Pharmaceuticals (IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.

Idera Pharma Earnings, Revenue Beat in Q3

Idera Pharmaceuticals press release (IDRA): Q3 GAAP EPS of -$0.06.Revenue of $0.05M.The Company’s pro forma cash position as of September 30, 2022 was $26.8 million.

EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better

Idera Pharmaceuticals Inc (NASDAQ: IDRA ) acquired Aceragen Inc , a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023 , funding the advancement of Aceragen''s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from … Full story available on Benzinga.com

Idera Pharmaceuticals (IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction.

Idera Pharmaceuticals press release (IDRA): Q4 GAAP EPS of -$0.08.The company''s cash position as of December 31, 2021 was $32.5 million

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

Carnival Corporation & plc (NYSE:CCL) with the stream of -0.24% also noticed, India Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) encountered a rapid change of -0.57% in the last hour of Thursdays trading The post Top RSI Trades for the day: Carnival Corporation & plc (NYSE:CCL), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) appeared first on Stocks Equity .

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) with the stream of 1.49% also noticed, India Tellurian Inc. (AMEX:TELL) encountered a rapid change of 0.68% in the last hour of Fridays trading session. Idera The post Bright Trending Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Tellurian Inc. (AMEX:TELL) appeared first on Stocks Equity .

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) with the stream of -25.28% also noticed, India Galiano Gold Inc. (AMEX:GAU) encountered a rapid change of -1.61% in the last hour of Wednesdays trading session. The post Beholding Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Galiano Gold Inc. (AMEX:GAU) appeared first on Stocks Equity .